CD8A and neoplasm: Bortezomib administration increased IFNγ and granzyme-B expression on Vβ8.1/2+CD8+T cells in tumor-bearing mice even in the presence of IL-12 and IL-15 neutralization antibody treatments, and restored them to the levels comparable to tumor-bearing mice treated with bortezomib only (Figure 5C).